“I’m thrilled that United Therapeutics continues to report double-digit revenue growth and our highest quarterly revenue ever,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer. “We expect this growth trajectory to continue with our current business as we expect to reach a $4 billion annual revenue run rate by mid-decade. Beyond that we expect continued waves of growth with an additional doubling of our revenue from the potential launch of Tyvaso in pulmonary fibrosis and ralinepag in pulmonary arterial hypertension, and then yet another doubling of our revenue with the potential for an unlimited supply of tolerable, transplantable organs in the next decade.”
UTHR今年的中期业绩有这一段：由于可能推出治疗肺纤维化的 Tyvaso 和治疗肺动脉高压的 Ralinepag会推动$联合治疗(UTHR)$ 年销量翻倍（40亿美金基础上）$云顶新耀-B(01952)$